AbbVie reported a third-quarter beat and raised its full-year profit outlook, citing strength across immunology and neuroscience as its stock continued to trade at record highs. CEO Rob Michael said the company has capacity for acquisitions but prefers bolt-on transactions rather than pursuing another large-scale megadeal like its 2020 Allergan purchase. AbbVie posted quarterly sales of $17.4 billion and EPS of $3.82, and raised full-year EPS guidance to a range of $13.95–$13.99. Guggenheim analysts framed the results as evidence that “the train” can keep moving as franchise performance remains resilient. Immunology drove the majority of the growth, with Skyrizi sales up 23% year over year to $5.7 billion and Rinvoq growing 24% to $2.7 billion, while neuroscience also expanded. William Blair highlighted neuroscience growth at 19% year over year to $3.4 billion, including Vraylar sales topping $1 billion and multi-product contribution across migraine and Parkinson’s. For investors, AbbVie’s update reinforces the company’s ability to fund strategy through operating performance while shaping a deals strategy designed to diversify and sustain growth beyond its most mature franchises.